Cure My Disease

Don't miss your cure!

 Log in / Sign up

Colon tissue may hold clues to telling Parkinson's apart from Look-Alike diseases

NCT ID NCT01353183

Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether tissue samples taken during a routine colon exam can help tell apart Parkinson's disease from two similar conditions: multiple system atrophy and progressive supranuclear palsy. The study includes 34 people aged 50 to 80, some with these conditions and some without, who are already scheduled for a colonoscopy or sigmoidoscopy. Doctors will look for clumps of a protein called alpha-synuclein in the colon tissue to see if this can serve as a diagnostic marker.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colonoscopy or rectosigmoidoscopy to collect colon tissue samples
What this could lead to
If the approach works, doctors could use a routine colon biopsy to tell apart Parkinson's disease from similar conditions earlier and more accurately.
What could go wrong
This is a small study of 34 people, and the biopsy test may not reliably distinguish these conditions. Colonoscopy carries small risks like bleeding or perforation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Start date

Nov 2010

Finished

Nov 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients * Patients aged 50-80 year old, both genders * Parkinson's disease patients * Multiple system atrophy patients * Progressive supranuclear palsy patients * Controls: patient at risk of colic cancer for whom a colonoscopy is required * Patients who signed the informed consent Controls * Patients aged 50 to 80 year-old for whom a rectosigmoidoscopy or a colonoscopy is required for colorectal screening * Patients who signed the informed consent * Health care beneficiary Exclusion Criteria: Patients * Colonic disorder (except non-complicated diverticular disease) * Other neurological disorder than parkinsonism * Patients treated with either platelet antiaggregants, anticoagulants or with a known coagulation disorder * Patients with a cognitive impairment that preclude them from understanding the informed consent * Patients placed under legal guardianship Controls * Neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease or other dementia, amyotrophic lateral sclerosis... * Functional bowel disorder such as irritable bowel syndrome * Patients with a cognitive impairment that preclude them from understanding the informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy Parkinson's disease Progressive supranuclear palsy

Contacts and locations

Locations

  • Nantes University Hospital

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.